{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T00:12:58Z","timestamp":1793059978801,"version":"4.5.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T00:00:00Z","timestamp":1652400000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.breast.2022.05.004","type":"journal-article","created":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T02:29:20Z","timestamp":1653013760000},"page":"100-111","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Long term outcome data from the EORTC 75111-10114 ETF\/BCG randomized phase II study: Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer, followed by T-DM1 after progression"],"prefix":"10.1016","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8990-7837","authenticated-orcid":false,"given":"Hans","family":"Wildiers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Meyskens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Marr\u00e9aud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lissandra Dal","family":"Lago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6401-3722","authenticated-orcid":false,"given":"Peter","family":"Vuylsteke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1781-2518","authenticated-orcid":false,"given":"Giuseppe","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0205-4398","authenticated-orcid":false,"given":"Simon","family":"Waters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Brouwers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Meulemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2287-4799","authenticated-orcid":false,"given":"Berta","family":"Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coralie","family":"Poncet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Brain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2022.05.004_bib1","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/ijc.31664","article-title":"Global cancer incidence in older adults, 2012 and 2035: a population-based study","volume":"144","author":"Pilleron","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.breast.2022.05.004_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5539\/gjhs.v10n11p1","article-title":"Breast cancer in europe: epidemiology, risk factors, policies and strategies. A literature review","volume":"10","author":"Aljohar","year":"2018","journal-title":"Global J Health Sci"},{"key":"10.1016\/j.breast.2022.05.004_bib3","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1200\/JOP.2015.010207","article-title":"Breast cancer in women older than 80 years","volume":"12","author":"Shachar","year":"2016","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.breast.2022.05.004_bib4","doi-asserted-by":"crossref","first-page":"908","DOI":"10.3390\/cancers7020815","article-title":"Effects of age on the detection and management of breast cancer","volume":"7","author":"McGuire","year":"2015","journal-title":"Cancers"},{"key":"10.1016\/j.breast.2022.05.004_bib5","first-page":"438","article-title":"Breast cancer statistics","volume":"69","author":"DeSantis","year":"2019","journal-title":"Ca - Cancer J Clin"},{"key":"10.1016\/j.breast.2022.05.004_bib6","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S1470-2045(20)30741-5","article-title":"Updated recommendations regarding the management of older patients with breast cancer: a joint paper from the European Society of Breast Cancer Specialists (EUSOMA) and the International Society of Geriatric Oncology (SIOG)","volume":"22","author":"Biganzoli","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2022.05.004_bib7","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jgo.2013.05.007","article-title":"HER2 status in elderly women with breast cancer","volume":"4","author":"Laird-Fick","year":"2013","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.breast.2022.05.004_bib8","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1634\/theoncologist.2014-0184","article-title":"Age\u2010specific changes in intrinsic breast cancer subtypes: a focus on older women","volume":"19","author":"Jenkins","year":"2014","journal-title":"Oncol"},{"key":"10.1016\/j.breast.2022.05.004_bib9","doi-asserted-by":"crossref","first-page":"e663","DOI":"10.1016\/S2666-7568(21)00179-3","article-title":"Is cancer biology different in older patients?","volume":"2","author":"Van Herck","year":"2021","journal-title":"Lancet Heal Longev"},{"key":"10.1016\/j.breast.2022.05.004_bib10","doi-asserted-by":"crossref","first-page":"100114","DOI":"10.1016\/j.esmoop.2021.100114","article-title":"Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort","volume":"6","author":"Grinda","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.breast.2022.05.004_bib11","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1056\/NEJMoa1413513","article-title":"Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer","volume":"372","author":"Swain","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2022.05.004_bib12","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2022.05.004_bib13","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S1470-2045(17)30313-3","article-title":"Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial","volume":"18","author":"Krop","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2022.05.004_bib14","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.jgo.2019.06.004","article-title":"HER2-targeted treatment for older patients with breast cancer: an expert position paper from the International Society of Geriatric Oncology","volume":"10","author":"Brain","year":"2019","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.breast.2022.05.004_bib15","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(18)30083-4","article-title":"Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force\/Breast Cancer Group","volume":"19","author":"Wildiers","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2022.05.004_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.jgo.2022.01.009","article-title":"Health-related quality of life in older patients with HER2+ metastatic breast cancer: comparing pertuzumab plus trastuzumab with or without metronomic chemotherapy in a randomised open-label phase II clinical trial","author":"Dal Lago","year":"2022","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.breast.2022.05.004_bib17","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ctrv.2015.11.009","article-title":"Taxanes in the treatment of breast cancer: have we better defined their role in older patients? A position paper from a SIOG Task Force","volume":"43","author":"Biganzoli","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.breast.2022.05.004_bib18","doi-asserted-by":"crossref","DOI":"10.1161\/CIR.0000000000000426","article-title":"Drugs that may cause or exacerbate heart failure","volume":"134","author":"Page","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.breast.2022.05.004_bib19","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1200\/JCO.2017.76.7863","article-title":"First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor receptor 2\u2013positive and hormone receptor\u2013positive metastatic or locally advanced breast cancer (PERTAIN): a randomized, open-label phase II tr","volume":"36","author":"Rimawi","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2022.05.004_bib20","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(20)30465-4","article-title":"Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial","volume":"21","author":"Emens","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2022.05.004_bib21","doi-asserted-by":"crossref","first-page":"S1287","DOI":"10.1016\/j.annonc.2021.08.2087","article-title":"LBA1 Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): results of the randomized phase III DESTINY-Breast03 study","volume":"32","author":"Cort\u00e9s","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2022.05.004_bib22","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1056\/NEJMp2106089","article-title":"Treatment of older adults with cancer \u2014 addressing gaps in evidence","volume":"385","author":"Bertagnolli","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2022.05.004_bib23","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/S2666-7568(20)30001-5","article-title":"Anticancer drugs are not well tolerated in all older patients with cancer","volume":"1","author":"Wildiers","year":"2020","journal-title":"Lancet Heal Longev"},{"key":"10.1016\/j.breast.2022.05.004_bib24","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1056\/NEJMoa0810266","article-title":"Adjuvant chemotherapy in older women with early-stage breast cancer","volume":"360","author":"Muss","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2022.05.004_bib25","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/S0140-6736(11)60399-1","article-title":"Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial","volume":"377","author":"Seymour","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2022.05.004_bib26","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.4006","article-title":"Optimizing chemotherapy for frail and elderly patients (pts) with advanced gastroesophageal cancer (aGOAC): the GO2 phase III trial","volume":"37","author":"Hall","year":"2019","journal-title":"J Clin Oncol"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977622000960?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977622000960?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:45:31Z","timestamp":1760777131000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977622000960"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":26,"alternative-id":["S0960977622000960"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2022.05.004","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long term outcome data from the EORTC 75111-10114 ETF\/BCG randomized phase II study: Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer, followed by T-DM1 after progression","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2022.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}